Business Wire

Stoli® Vodka Says It “Loud and Clear” with New Global Advertising Campaign

Del

Stoli® Vodka, the original premium vodka with uncompromising quality for the past 80 years, announced today the launch of their new global advertising campaign, “Loud and Clear.” The provocative new campaign features work from award-winning artists like composer Hans Zimmer, Lorne Balfe and director Rachel Morrison. The campaign takes a 360-approach, incorporating television, digital, social and print to reveal Stoli®’s unapologetic message – whatever drives you, make it bold, make it last, make it loud and clear.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180516006326/en/

Famed photographer Rankin led the print creative for Stoli Vodka's "whatever drives you, make it lou ...

Famed photographer Rankin led the print creative for Stoli Vodka's "whatever drives you, make it loud and clear" advertising campaign, which the brand introduced earlier this week.

The release of the “Loud and Clear” campaign demonstrates Stoli’s unwavering presence in the spirits industry, while differentiating itself as the real deal in today’s vodka sea of sameness. Shot in Ukraine, each creative spot showcases real people celebrating their unique identities and what drives them. The footage makes it “Loud and Clear” that they are fully embracing their style, passions and beliefs with conviction.

“Our new advertising campaign truly captures the boldness and clarity of Stoli,” said Hugues Pietrini, Global President & CEO of Stoli® Group. “With an 80-year history in the spirits category, we are proud of our brand identity and values and want our fans to feel the same. We encourage them to ‘make it loud and clear’ that they are embracing and broadcasting their true selves without inhibition.”

Developed with FF New York, the global creative agency founded by Fred & Farid, “Loud and Clear” boasts an impressive lineup of award-winning creative talent who contributed to the campaign. “Loud and Clear” features music from the Oscar-winning composer, Hans Zimmer, and Emmy/BAFTA-nominated composer Lorne Balfe, which elevates the drama and emotion in the piece.

Oscar Nominee Rachel Morrison served as the campaign’s director of photography on the video, which was shot by directors “We are From LA”. The print creative was shot by esteemed photographer Rankin in London and features the designs of graphic artist Tyrsa, who created a brand new font, Stoli Brush, for all of the print ads. The font will be made accessible for Stoli fans and consumers alike to download and use for free.

“A new campaign for Stoli needed both a bold, new positioning from the brand and the right creative community to bring it to life,” said Fred & Farid, founders of FF. “As such, we worked with distinctive, visionary artists who are uncompromising in their values. The work of Mr. Zimmer, Mr. Balfe and Ms. Morrison were an incredible fit for the spirit of the brand.”

For more information, visit www.stoli.com or follow Stoli Vodka on Instagram @Stoli, on Facebook at www.facebook.com/stoli and on Twitter @Stoli.

About Stoli Group ®

Part of SPI Group – one of the world's leading premium spirits businesses – Stoli Group was established in 2013 as the division responsible for the management, distribution and marketing of SPI's global spirit portfolio.

Contact information

Stoli Group
Alison Walsh, +1-917-301-2962
awalsh@stoli.com
or
MWW PR
Leslie Norden, +1-323-798-3925
lnorden@mww.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Ultra-Low Power Lattice sensAI Leads Mass Market Enablement of Artificial Intelligence in Edge Devices21.5.2018 12:00Pressemelding

Lattice Semiconductor Corporation (NASDAQ: LSCC) today unveiled Lattice sensAI™ – a complete technology stack combining modular hardware kits, neural network IP cores, software tools, reference designs and custom design services – to accelerate integration of machine learning inferencing into broad market IoT applications. With solutions optimized for ultra-low power consumption (under 1 mW–1 W), small package size (5.5 mm2 –100 mm2), interface flexibility (MIPI® CSI-2, LVDS, GigE, etc.), and high-volume pricing (~$1-$10 USD), Lattice sensAI stack fast-tracks implementation of edge computing close to the source of data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005011/en/ (Graphic: Business Wire) “Lattice sensAI addresses the unmet need for flexible, low cost, ultra-low power AI silicon solutions suited for rapid deployment across a wide range of emerging, mass market IoT applications,” said Deepak Boppana, senior

NioCorp Awards Contract to Rockwell Automation on Groundbreaking Critical Minerals, Mining and Processing Facility in Nebraska21.5.2018 12:00Pressemelding

NioCorp Developments Ltd. (TSX: NB, OTCQX: NIOBF), a developer of superalloy metals, has awarded a major contract to Rockwell Automation (NYSE: ROK) to engineer, design and procure process automation and instrumentation for NioCorp’s proposed critical minerals, mining and processing facility in Elk Creek, Nebraska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005228/en/ Three superalloy metals – niobium, scandium and titanium – are expected to be produced by the facility as early as 2021. These critical materials are used in the aerospace, defense, automotive, clean energy, commercial aviation and mega-infrastructure sectors. Generally, these superalloys enable increased strength and lighter weight in transportation and other systems, leading to better fuel efficiency and lower greenhouse gas and other air emissions, according to NioCorp. “We selected Rockwell Automation and its partners to automate our process equip

Biosimilars could facilitate early access to life changing biological treatments for patients says Celltrion Healthcare21.5.2018 11:27Pressemelding

At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Celltrion Healthcare today advocated for healthcare systems to introduce biologics earlier in a patient’s treatment regimen in order to improve clinical outcomes. Several studies show that the early introduction of biologics can bring greater clinical benefit to patients.1,2,3,4,5,6 However, only a limited number of patients have access to biological treatment due to the high-cost of biologics and current reimbursement policies determined by pharmacoeconomic evaluations. Since the introduction of biosimilars, the overall cost of biological treatments has reduced in Europe, allowing an increased number of patients to access this important treatment option earlier in their course of treatment.7 Professor Jørgen Jahnsen said, “For the treatment of inflammatory bowel disease, biological treatments are proven to be the most efficacious medical therapy and their ea

Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 11:00Pressemelding

Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba

ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV21.5.2018 10:11Pressemelding

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1 Juluca is a 2-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide,2 and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson).1 Deborah Waterhouse, CEO ViiV Healthcare said, “The European Commission Decision for Juluca is very positive news for people living with

Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-121.5.2018 10:06Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA® (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences Ireland UC]).1 ViiV Healthcare, as the marketing authorisation holder, will market dolutegravir/rilpivirine in all countries in the European Union and European Economic Area. Dolutegravir/rilpivirine is the first two-drug regimen, once-daily, single-pill for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor (INI).1 “The European Commission Decision for dolutegravir/rilpivirine marks a significant milestone in our 25-year commitment to make HIV history,” said Brian Woo